Atisa Lifesciences

Hyderabad, India Founded: 2018 • Age: 8 yrs
Manufactures and supplies affordable medicines in oncology, nephrology, and hepatology sectors.
Annual revenue $63,580 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 5 Services tracked
Competitors - Brand Intelligence

About Atisa Lifesciences

Atisa Lifesciences is a company based in Hyderabad (India) founded in 2018. It operates as a B2B and Manufacturing and Distribution. Atisa Lifesciences offers products and services including Futran, Tidar, Peglip, Zyterone, and Lenodo.

  • Headquarter Hyderabad, India
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Atisa Life Sciences Private Limited
  • Date of Incorporation 21 Dec, 2010
  • Jurisdiction Hyderabad, Telangana, India
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $63.58 K (USD)
    -4.47
    as on Mar 31, 2022
  • Net Profit
    -$64.63 K (USD)
    15.03
    as on Mar 31, 2022
  • EBITDA
    -$37.76 K (USD)
    38.33
    as on Mar 31, 2022
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Atisa Lifesciences

Atisa Lifesciences offers a comprehensive portfolio of products and services, including Futran, Tidar, Peglip, Zyterone, and Lenodo.

Product name locked
Category locked
Primary

Fulvestrant injection for treating breast cancer patients

Product name locked
Category locked
Locked

Temozolomide injection used in brain tumor therapy

Product name locked
Category locked
Locked

Pegylated liposomal doxorubicin for cancer treatment

Product name locked
Category locked
Locked

Abiraterone acetate tablets for prostate cancer care

Product name locked
Category locked
Locked

Lenalidomide capsules for multiple myeloma management

Funding Insights of Atisa Lifesciences

Premium access

Detailed funding history for Atisa Lifesciences

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Atisa Lifesciences

Investments
Premium access

Investment portfolio details for Atisa Lifesciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Atisa Lifesciences

Premium access

Detailed financials for Atisa Lifesciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Atisa Lifesciences Comparisons

Atisa Lifesciences Primary company
Description
Manufactures and supplies affordable medicines in oncology, ...
Location
Hyderabad, India
Founded Year
2018
Annual Revenue
$63.58 K (USD)
Net Profit
-$64.63 K (USD)
EBITDA
-$37.76 K (USD)
Employees
Not available
Premium access

Peer comparison for Atisa Lifesciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Atisa Lifesciences

Premium access

Detailed competitors of Atisa Lifesciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Atisa Lifesciences

Premium access

Complete news archive for Atisa Lifesciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Atisa Lifesciences

Atisa Lifesciences was founded in 2018.

Atisa Lifesciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Annual revenue of Atisa Lifesciences is $63.58K as on Mar 31, 2022.

Atisa Lifesciences is a specialty pharmaceutical company based in India, emphasizing high-quality medicine production adhering to GMP guidelines. It focuses on therapeutic areas like oncology, nephrology, and hepatology, developing innovative drugs through research and collaboration. The company aims to improve patient survival and quality of life by providing affordable treatments globally, with manufacturing processes ensuring regulatory compliance and stringent standards.

Atisa Lifesciences offers Futran, Tidar, Peglip, Zyterone, and Lenodo.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available